




CLASRP, MARK4 (GH19J045307) enhancer gain
chr19:45308035–45308535

Putatively Subclonal

	LogFC	P.	Adjusted P.
<i>Adenoma vs. normal</i>	-0.28	NA	NA
<i>Adenoma vs. Cancer ~purity+type</i>	-3.57	3.55e-03 **	3.91e-02 *




FOXQ1 promoter gain
chr6:1311742-1312242




Putatively Subclonal

	LogFC	P.	Adjusted P.
<i>Adenoma vs. normal</i>	2.85	5.24e-07 ****	5.24e-07 ****
<i>Adenoma vs. Cancer ~purity+type</i>	2.57	1.49e-03 **	2.88e-02 *




RGS13 (GH01J192608) enhancer loss chr1:192609034–192609534




Putatively Subclonal

	LogFC	P.	Adjusted P.
<i>Adenoma vs. normal</i>	-2.93	1.42e-03 **	1.42e-03 **
<i>Adenoma vs. Cancer ~purity+type</i>	-4.53	3e-03 **	3.84e-02 *




ZNF43 promoter loss
chr19:21851889–21852389




Putatively Subclonal

	LogFC	P.	Adjusted P.
<i>Adenoma vs. normal</i>	-3.83	1e-08 ****	1e-08 ****
<i>Adenoma vs. Cancer ~purity+type</i>	-3.63	3.49e-05 ****	8.96e-04 ***



CLASRP, MARK4 (GH19J045307) enhancer gain


chr19:45308035-45308535



Putatively Subclonal


*Adenoma vs. normal**F vs. Cancer ~purity+type**G vs. Cancer ~purity+type*

LogFC	P.	Adjusted P.
-0.94	4.98e-02 *	4.98e-02 *
-4.19	2.87e-04 ***	6.12e-03 **
-5.53	2.28e-05 ****	1.39e-03 **



ENSG00000253931 (GH08J143405) enhancer gain

chr8:143407862-143408362




Putatively Subclonal

Adenoma vs. normal


F vs.Cancer ~purity+type

G vs.Cancer ~purity+type

LogFC	P.	Adjusted P.
-0.94	4.98e-02 *	4.98e-02 *
-3.64	1.05e-04 ***	3.35e-03 **
-4.03	6.69e-05 ****	2.04e-03 **



NXPH1 (GH07J008389) enhancer gain
chr7:8389807–8390307




Putatively Subclonal

Adenoma vs. normal


F vs. Cancer ~purity+type

G vs. Cancer ~purity+type

	LogFC	P.	Adjusted P.
<i>Adenoma vs. normal</i>	-0.94	4.98e-02 *	4.98e-02 *
<i>F vs. Cancer ~purity+type</i>	-2.99	4.27e-03 **	5.47e-02
<i>G vs. Cancer ~purity+type</i>	-3.23	3.58e-03 **	3.64e-02 *



PRR36 promoter gain
chr19:7870611–7871111




Putatively Subclonal

Adenoma vs. normal

F vs. Cancer ~purity+type


G vs. Cancer ~purity+type

LogFC	P.	Adjusted P.
-0.94	4.98e-02 *	4.98e-02 *
-3.79	2.59e-05 ****	1.66e-03 **
-2.49	2.58e-03 **	3.14e-02 *



RNLS, LIPJ (GH10J088553) enhancer loss

chr10:88553102–88553602




Putatively Subclonal

Adenoma vs. normal


F vs.Cancer ~purity+type

G vs.Cancer ~purity+type

	LogFC	P.	Adjusted P.
<i>Adenoma vs. normal</i>	-0.94	4.98e-02 *	4.98e-02 *
<i>F vs.Cancer ~purity+type</i>	-4.84	4.02e-03 **	5.47e-02
<i>G vs.Cancer ~purity+type</i>	-5.51	2.47e-03 **	3.14e-02 *



SLC45A4 promoter gain
chr8:141230663–141231163




Putatively Subclonal

Adenoma vs. normal



F vs. Cancer ~purity+type

G vs. Cancer ~purity+type

LogFC	P.	Adjusted P.
-0.94	4.98e-02 *	4.98e-02 *
-2.22	5.79e-02	2.32e-01
-3.78	6.2e-03 **	5e-02 *



TEX26 (GH13J030867) enhancer gain
chr13:30870352–30870852




Putatively Subclonal

Adenoma vs. normal


F vs. Cancer ~purity+type

G vs. Cancer ~purity+type

	LogFC	P.	Adjusted P.
<i>Adenoma vs. normal</i>	-0.94	4.98e-02 *	4.98e-02 *
<i>F vs. Cancer ~purity+type</i>	-1.99	5.43e-03 **	5.79e-02
<i>G vs. Cancer ~purity+type</i>	-3.21	1.11e-04 ***	2.26e-03 **



TTYH3 promoter gain
chr7:2646791–2647291



Putatively Subclonal

Adenoma vs. normal

	LogFC	P.	Adjusted P.
<i>Adenoma vs. normal</i>	-0.94	4.98e-02 *	4.98e-02 *
<i>F vs.Cancer ~purity+type</i>	-2.91	1.16e-02 *	8.87e-02
<i>G vs.Cancer ~purity+type</i>	-3.44	6.55e-03 **	5e-02 *

